Myriad Genetics (MYGN) Total Non-Current Liabilities (2010 - 2026)

Myriad Genetics has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $334.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 11.83% year-over-year to $334.6 million; the TTM figure through Mar 2026 stood at $334.6 million (up 11.83% YoY), while the FY2025 annual figure was $336.7 million, up 3.82% from the prior year.
• Total Non-Current Liabilities declined to $334.6 million in Q1 2026, from $336.7 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for MYGN reached as high as $440.6 million in Q2 2023 and fell as low as $258.1 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $315.2 million (2023), against an average of $320.4 million.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 39.54% — and 2023, when it surged 70.71%.
• A 5-year view of Total Non-Current Liabilities shows it stood at $269.0 million in 2022, then climbed by 17.17% to $315.2 million in 2023, then gained by 2.89% to $324.3 million in 2024, then grew by 3.82% to $336.7 million in 2025, then retreated by 0.62% to $334.6 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $334.6 million, $336.7 million, and $353.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.